Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
Patients should ask what symptoms need evaluation first, what labs may help, whether peptide therapy is appropriate, what benefits are realistic, what risks are unknown, and how progress would be monitored
Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat
PlexusDx supports patients across all 50 states and understands travel planning requirements
Sources and references MHRA / GOV.UK: First GLP-1 tablet for weight loss approved in the UK NHS: Overweight and obesity in adults NICE NG246: Medicines for overweight and obesity New England Journal of Medicine: Oral semaglutide 25 mg in adults with overweight or obesity European Medicines Agency: Wegovy tablets for oral use positive opinion MHRA Drug Safety Update: Semaglutide and NAION MHRA Yellow Card: report a suspected side effect MHRA / GOV.UK: GLP-1 medicines for weight loss and diabetes MHRA Products: official SmPC and patient leaflets UK prescribing decisions should follow UK regulatory information, the prescriber's clinical assessment and the official UK product information when published
